Tuesday, July 21, 2026

#cell therapy

6 articles

FDA PDUFA Wave in 2026 Sets Up Binary Catalyst Season Across ADC, Cell Therapy, and Checkpoint Inhibitor Portfolios

Biotech Investment

FDA PDUFA Wave in 2026 Sets Up Binary Catalyst Season Across ADC, Cell Therapy, and Checkpoint Inhibitor Portfolios

Salvado•Jun 19, 2026

H2 2026 FDA Decision Cluster Forces Biotech Repricing Across ADCs and Cell Therapies

Biotech Investment

H2 2026 FDA Decision Cluster Forces Biotech Repricing Across ADCs and Cell Therapies

Salvado•Jun 17, 2026

Gilead-Backed Lakefront Closes Ouro Medicines Deal, Keeps $500M for Further Autoimmune Acquisitions

Gilead-Backed Lakefront Closes Ouro Medicines Deal, Keeps $500M for Further Autoimmune Acquisitions

Salvado•Jun 13, 2026

FDA Priority Reviews and Cell Therapy Acquisitions Signal Biotech Sector Acceleration

Healthcare & Pharma Investment

FDA Priority Reviews and Cell Therapy Acquisitions Signal Biotech Sector Acceleration

Salvado•Apr 16, 2026

Artiva Biotherapeutics faces capital shortfall risk ahead of pivotal NK cell therapy trials

Corporate Finance

Artiva Biotherapeutics faces capital shortfall risk ahead of pivotal NK cell therapy trials

ViaNews Editorial Team (Finance)•Mar 7, 2026

Biotech's Commercial Inflection: What the Gene Therapy and mRNA Pipeline Surge Means for Investors

Healthcare Finance

Biotech's Commercial Inflection: What the Gene Therapy and mRNA Pipeline Surge Means for Investors

ViaNews Editorial Team (Finance)•Feb 18, 2026